Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-23T08:06:15.244Z Has data issue: false hasContentIssue false
  • English
  • Français

Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties

Published online by Cambridge University Press:  05 June 2014

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Abstract

ISSUE:A striking and unexpected pharmacologic synergy has been shown between antagonist actions at serotonergic 5HT2C receptors, and agonist actions at melatonergic receptors by agomelatine, a drug that has both of these properties.

Type
Brainstorms
Information
CNS Spectrums , Volume 19 , Issue 3 , June 2014 , pp. 207 - 212
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Stahl, SM. Stahl's Essential Psychopharmacology, 4th ed. New York: Cambridge University Press; 2013.Google Scholar
2.De Bodinat, C, Guardiola-Lemaitre, B, Mocaer, E. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010; 9(8): 928–942.Google ScholarPubMed
3.Zajecka, J, Schatzberg, A, Stahl, S, etal. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010; 30(2): 135–144.Google Scholar
4.Stahl, SM, Fava, M, Trivedi, M, etal. Agomelatine in the treatment of major depressive disorder: an 8 week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010; 71(5): 616–626.CrossRefGoogle ScholarPubMed
5.Chenu, F, El Mansari, M, Blier, P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain. Neuropsychopharmacology. 2013; 38(2): 275–284.Google Scholar
6.Molteni, R, Calabrese, F, Pisoni, S, etal. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine. World J Biol Psychiatry. 2010; 11(2): 148–153.Google Scholar
7.Tardito, D, Milanese, M, Bonifacino, T, etal. Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways. BMC Neurosci. 2010; 11: 68.CrossRefGoogle ScholarPubMed
8.Nutt, D, Demyttenaere, K, Janka, Z, etal. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007; 21(5): 461–471.CrossRefGoogle ScholarPubMed
9.Martinotti, G, Sepede, G, Gambi, F, etal. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. 2012; 32(4): 487–491.CrossRefGoogle ScholarPubMed
10.Corruble, E, de Bodinat, C, Belaidi, C, Goodwin, GM; Agomelatine Study Group. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-week randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013; 16(10): 2219–2234.Google Scholar
11.Lemoine, P, Guilleminault, C, Alvarez, E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007; 68(11): 1723–1732.CrossRefGoogle ScholarPubMed
12.Quera-Salva, MA, Hajak, G, Philip, P, etal. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011; 26(5): 252–262.Google Scholar
13.Kennedy, SH, Rizvi, S, Fulton, K, Rasmussen, J. A double-blind comparison of sexual functioning, antidepressant efficacy and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008; 28(3): 329–333.Google Scholar